FDA Grants Accelerated Approval to Avlayah for Children With Hunter Syndrome
A new drug, Avlayah, has received accelerated approval from the FDA, offering a new treatment option for children with rare Hunter syndrome (MPS II). This drug is significant because it targets neurological aspects of the disease by crossing the blood-brain…
Terre Haute, IN, October 21, 2026 —
The Food and Drug Administration has granted accelerated approval to Avlayah, a new treatment option for children with Hunter syndrome, also known as MPS II. The drug is described as targeting neurological aspects of the rare disease by crossing the blood-brain barrier.
The approval marks a treatment development for families who have had limited options for addressing physical symptoms, according to the information provided. The summary does not specify which physical symptoms those treatments address or identify the other available treatments.
Clinical trials, including one conducted at UNC Health in Chapel Hill, North Carolina, have shown promising results, the summary says. Avlayah is intended to slow disease progression and improve outcomes for affected children. No trial results, participant numbers, study dates or measures of improvement were provided, so the scale and duration of the reported effects are not specified.
The summary also does not state when the FDA issued its decision, the terms of the accelerated approval, or what further evidence may be required. It does not provide details about the trial at UNC Health or identify other participating institutions. The drug’s manufacturer, availability, dosing information and potential side effects were not included.
Avlayah’s ability to cross the blood-brain barrier is presented as a key distinction in its approach to neurological aspects of Hunter syndrome. However, the information provided does not describe how the drug works beyond that point or quantify its effects. The available account therefore establishes the approval and the treatment’s stated aim, while leaving clinical details and next steps unspecified.
Story summarized from the original created by Tisha Powell, Stacy Wimmer on www.wthitv.com, see more information here.
Media gallery
